According to the Public Relations and International Affairs Unit of Parand Darou Company, one of the successful companies at the Pharmex exhibition was the international company Safe Pharma. The visit of Parand Darou’s colleagues to Safe Pharma’s booth was made at the invitation of Dr. Hossein Monfared and Ms. Katy, senior managers at Safe Pharma. This visit provided an opportunity to explore bilateral collaborations and assess the capabilities of both companies.
Safe Pharma is a leading company in the pharmaceutical industry, specializing in the production and supply of raw pharmaceutical materials, pharmaceutical industry equipment, and intermediate pharmaceutical products. Utilizing advanced technologies and a skilled team of experts, the company has managed to produce high-quality products that meet global standards. Among its prominent products are Parkocib, Metolazone, and One H Hydrozole, each serving specific applications in various fields of pharmaceuticals.
Parkocib is a key product of Safe Pharma, used as an essential raw material in the production of anti-inflammatory and pain-relieving medications. Due to its high purity and strong efficacy, it has attracted the attention of many pharmaceutical companies. Metolazone is another product from the company, used as a potent diuretic in the treatment of cardiovascular diseases. One H Hydrozole, also an intermediate pharmaceutical product, plays a crucial role in the production of anti-cancer drugs and treatments for chronic diseases.
During this visit, Parand Darou’s team engaged in discussions with Safe Pharma’s managers and specialists regarding their capabilities and available resources. These discussions aimed at exchanging ideas and exploring areas of mutual cooperation. One of the main objectives of the visit was to identify new opportunities for strategic collaboration and to leverage the strengths of both companies.
Bilateral collaborations between pharmaceutical companies can lead to strengthening the supply chain, improving product quality, and accelerating the development of new drugs. In this context, Parand Darou and Safe Pharma, given their expertise and experiences, can complement each other and benefit from this mutually advantageous collaboration.
Another topic discussed during the visit was the review of innovations and new technologies in the pharmaceutical industry. Both companies, utilizing cutting-edge technologies, strive to deliver higher-quality products to the market and better address the needs of patients and the pharmaceutical industry.
In conclusion, the visit highlighted that both Parand Darou and Safe Pharma, with their significant capabilities and resources, can achieve their long-term goals through bilateral collaborations. Such partnerships not only contribute to improving quality and increasing efficiency in pharmaceutical product manufacturing but also play a crucial role in advancing the pharmaceutical industry and enhancing public health.
Overall, Parand Darou’s presence at Safe Pharma’s booth at the Pharmex exhibition provided a valuable opportunity to explore and assess potential areas for joint cooperation and the exchange of ideas and experiences, which could lead to further development and progress for both companies.
